Affiliation:
1. Department of Medicine Hôpital Maisonneuve‐Rosemont Montreal Quebec Canada
2. Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine Stanford University School of Medicine Stanford California USA
Abstract
AbstractAutologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T‐cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post‐AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow‐up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse. As expected, more patients who were not in first complete remission experienced post‐AHCT relapse. Following relapse, majority of the patients (70%) receiving systemic therapies intended as bridging to curative allogeneic HCT. However, only 18 (53%) patients eventually underwent allogeneic HCT. The estimated 3‐year OS among patients proceeding to allogeneic HCT was 72% (95% CI 46%–87%). Our report details the pattern of post‐AHCT relapse and the management of relapsed disease using different therapeutic modalities.